Knight Therapeutics (KHTRF) 6.9988 $KHTRF
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Knight Therapeutics: Minimal Downside For This Misunderstood Company
Understanding Businesses - at Seeking Alpha - Thu Jan 29, 1:06PM CST
Synergy Strips Corp. Acquires Assets of America's No.1 Brain Health Supplement, FOCUSfactor
Business Wire - Mon Jan 26, 4:25PM CST
Synergy Strips Corp. (OTCQB:SNYR) ("Synergy"
, a company that markets and distributes consumer products primarily in the health and wellness industry, today announced the acquisition of the FOCUSfactor(R) brand, America's No.1 brain health supplement, from Factor Nutrition Labs, LLC. Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries ("Knight" , financed the transaction with a $6 million secured loan. FOCUSfactor is sold at retail stores including Costco, Sam's Club, Walmart, Walgreens, CVS and The Vitamin Shoppe.
VSI: 43.90 (+0.62), GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement
Marketwired - Thu Jan 22, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight" , announced today that it has entered into a senior secured debt financing agreement with Synergy Strips Corp. (OTCQB: SNYR) ("Synergy" , a US company focused on the health and wellness sector. The secured loan will fund Synergy's acquisition of the FOCUSfactor brand, the United States' #1 brain health supplement.
GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. Announces Board Change
Marketwired - Wed Jan 21, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight's Board of Directors. "Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date," said Jonathan Ross Goodman, President and CEO of Knight. "In his place, we welcome Ed Schutter, founder and CEO of US specialty pharmaceutical Arbor Pharmaceuticals, LLC., to our leadership team. Ed is a proven pharmaceutical entrepreneur."
GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon's Innovative Products
Marketwired - Thu Jan 01, 7:01AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company" , a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. ("NeurAxon" for the commercialization of NeurAxon's innovative products in various stages of development ("Pharmaceuticals" in Canada, Israel, South Africa and Russia ("Territory" .
GUD.TO: 8.70 (-0.05)
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Dec 16, 7:04AM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight" , announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. ("Domain Fund" and US$10 million in Sanderling Ventures VII, L.P. ("Sanderling Fund" . These investments into proven successful life science funds complement Knight Therapeutics Inc.'s US$13 million investment in Sectoral, EUREUR19.5 million investment in Forbion, and CAD$30 million investment in Teralys. These five funds have combined assets under management in healthcare of approximately CAD$9 billion.
GUD.TO: 8.70 (-0.05)
IIROC Trade Resumption - Knight Therapeutics Inc.
Newsfile Corp - Thu Dec 04, 7:45AM CST
Trading resumes in:
IIROC Trade Halt - Knight Therapeutics Inc.
Newsfile Corp - Wed Dec 03, 3:10PM CST
The following issues have been halted by IIROC:
Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement
Marketwired - Tue Dec 02, 9:15AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, announced today that it has entered into a senior secured debt agreement with CRH Medical Corporation (TSX: CRH)(OTCQX: CRMMF) ("CRH" , a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. This secured loan will fund CRH's acquisition of Gastroenterology Anesthesia Associates, LLC and GAA Management, LCC, collectively a Southeast US-based Anesthesia services provider ("GAA" .
CRH.TO: 2.91 (+0.10), GUD.TO: 8.70 (-0.05)
Humanitarian groups take issue with Knight Therapeutics' PRV windfall
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 8:22AM CST
GILD: 101.90 (+1.10)
Knight Sells Priority Review Voucher to Gilead
Marketwired - Wed Nov 19, 4:11PM CST
Knight Therapeutics Inc., (TSX: GUD) through one of its wholly owned subsidiaries ("Knight" , today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV" . The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC.
GILD: 101.90 (+1.10), GUD.TO: 8.70 (-0.05)
Knight Reports Third Quarter 2014 Results
Marketwired - Wed Nov 12, 5:02AM CST
Knight Therapeutics Inc. ("Knight" (TSX: GUD) today reported its financial results for the quarter ended September 30, 2014.
GUD.TO: 8.70 (-0.05)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Knight Therapeutics: Minimal Downside For This Misunderstood Company
Understanding Businesses - at Seeking Alpha - Thu Jan 29, 1:06PM CST
Synergy Strips Corp. Acquires Assets of America's No.1 Brain Health Supplement, FOCUSfactor
Business Wire - Mon Jan 26, 4:25PM CST
Synergy Strips Corp. (OTCQB:SNYR) ("Synergy"
, a company that markets and distributes consumer products primarily in the health and wellness industry, today announced the acquisition of the FOCUSfactor(R) brand, America's No.1 brain health supplement, from Factor Nutrition Labs, LLC. Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries ("Knight" , financed the transaction with a $6 million secured loan. FOCUSfactor is sold at retail stores including Costco, Sam's Club, Walmart, Walgreens, CVS and The Vitamin Shoppe. VSI: 43.90 (+0.62), GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement
Marketwired - Thu Jan 22, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight"
, announced today that it has entered into a senior secured debt financing agreement with Synergy Strips Corp. (OTCQB: SNYR) ("Synergy" , a US company focused on the health and wellness sector. The secured loan will fund Synergy's acquisition of the FOCUSfactor brand, the United States' #1 brain health supplement. GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. Announces Board Change
Marketwired - Wed Jan 21, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight's Board of Directors. "Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date," said Jonathan Ross Goodman, President and CEO of Knight. "In his place, we welcome Ed Schutter, founder and CEO of US specialty pharmaceutical Arbor Pharmaceuticals, LLC., to our leadership team. Ed is a proven pharmaceutical entrepreneur." GUD.TO: 8.70 (-0.05)
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon's Innovative Products
Marketwired - Thu Jan 01, 7:01AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. ("NeurAxon" for the commercialization of NeurAxon's innovative products in various stages of development ("Pharmaceuticals" in Canada, Israel, South Africa and Russia ("Territory" . GUD.TO: 8.70 (-0.05)
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Dec 16, 7:04AM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight"
, announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. ("Domain Fund" and US$10 million in Sanderling Ventures VII, L.P. ("Sanderling Fund" . These investments into proven successful life science funds complement Knight Therapeutics Inc.'s US$13 million investment in Sectoral, EUREUR19.5 million investment in Forbion, and CAD$30 million investment in Teralys. These five funds have combined assets under management in healthcare of approximately CAD$9 billion. GUD.TO: 8.70 (-0.05)
IIROC Trade Resumption - Knight Therapeutics Inc.
Newsfile Corp - Thu Dec 04, 7:45AM CST
Trading resumes in:
IIROC Trade Halt - Knight Therapeutics Inc.
Newsfile Corp - Wed Dec 03, 3:10PM CST
The following issues have been halted by IIROC:
Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement
Marketwired - Tue Dec 02, 9:15AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a senior secured debt agreement with CRH Medical Corporation (TSX: CRH)(OTCQX: CRMMF) ("CRH" , a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. This secured loan will fund CRH's acquisition of Gastroenterology Anesthesia Associates, LLC and GAA Management, LCC, collectively a Southeast US-based Anesthesia services provider ("GAA" . CRH.TO: 2.91 (+0.10), GUD.TO: 8.70 (-0.05)
Humanitarian groups take issue with Knight Therapeutics' PRV windfall
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 8:22AM CST
GILD: 101.90 (+1.10)
Knight Sells Priority Review Voucher to Gilead
Marketwired - Wed Nov 19, 4:11PM CST
Knight Therapeutics Inc., (TSX: GUD) through one of its wholly owned subsidiaries ("Knight"
, today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV" . The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC. GILD: 101.90 (+1.10), GUD.TO: 8.70 (-0.05)
Knight Reports Third Quarter 2014 Results
Marketwired - Wed Nov 12, 5:02AM CST
Knight Therapeutics Inc. ("Knight"
(TSX: GUD) today reported its financial results for the quarter ended September 30, 2014. GUD.TO: 8.70 (-0.05)
